Two months after closing its multibillion-dollar acquisition of Mirati Therapeutics, Bristol Myers Squibb is bidding adieu to ...
The agency gave Akebia’s drug an OK after receiving more safety data, but imposed a strict boxed warning for its use that may limit uptake.
In 2022, NeuGen informed MassMutual they were laying off 110 employees. According to the suit, MassMutual declared a total termination of the Agreement and gave the Fund to the Plan participants at ...
Plus: A breakthrough in treating food allergies. All in The Temperature, a weekly newsletter covering climate, health and ...
“Immatics kicked off 2024 with a successful capital raise ... this asset toward a registration-enabling Phase 2/3 clinical trial in melanoma, while laying the groundwork to transition into a fully ...